Joseph S. Zakrzewski - 10 Apr 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Reporting relationship: Director
Issuer ticker: ANTX
Reported as of: 10 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Apr 2025, 17:08:46 UTC
Prior SEC filing: 23 Dec 2024
Next SEC filing: 23 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Lucy Day, Attorney-in-Fact for Joseph S. Zakrzewski

Key filing fact

Joseph S. Zakrzewski filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 11 Apr 2025.

Key facts

This page summarizes Joseph S. Zakrzewski's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Apr 2025, 17:08.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Shares, units, or other non-derivative securities reported in this filing.

ANTX transaction

Award

ANTX holding

No transaction description listed

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 2 footnotes

Footnote F1

Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Footnote F2

These shares are held by Z3 Trust, for which the Reporting Person is a trustee.